The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Must have histologically or cytologically confirmed adenocarcinoma of the prostate Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria:
Prior treatment with an androgen receptor (AR) degrader Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP Clinically significant venous thromboembolism within 3 months prior to the first dose of IP Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
Other protocol-defined inclusion/exclusion criteria apply
